CO6290706A2 - Combinacion sinergica de un agonista nicotinico alfa 7 y un agente antipsicotico - Google Patents
Combinacion sinergica de un agonista nicotinico alfa 7 y un agente antipsicoticoInfo
- Publication number
- CO6290706A2 CO6290706A2 CO10112124A CO10112124A CO6290706A2 CO 6290706 A2 CO6290706 A2 CO 6290706A2 CO 10112124 A CO10112124 A CO 10112124A CO 10112124 A CO10112124 A CO 10112124A CO 6290706 A2 CO6290706 A2 CO 6290706A2
- Authority
- CO
- Colombia
- Prior art keywords
- nicotinic agonist
- combination
- pharmaceutical combination
- alfa
- antipsychotic agent
- Prior art date
Links
- 239000000181 nicotinic agonist Substances 0.000 title abstract 3
- 230000002195 synergetic effect Effects 0.000 title abstract 3
- 239000000164 antipsychotic agent Substances 0.000 title 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000010365 information processing Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
1.- Una combinación farmacéutica que comprende:al menos un agonista nicotínico a7; y al menos un agente antisicótico, donde la combinación provea una terapia sinérgica para un desorden psiquiátrico.2.- La combinación farmacéutica de la solicitud 1, donde el desorden psiquiátrico es un desorden psicótico.3.- La combinación farmacéutica de la solicitud 1 y la solicitud 2, donde el desorden psiquiátrico es esquizofrenia.4.- La combinación farmacéutica de la solicitudes 1-3, donde la combinación provea una terapia sinérgica para uno o más desordenes de atención, procesamiento de información, desordenes de memoria, o deficiencias en la función ejecutiva.5.- La combinación farmacéutica de la solicitudes 1-4, donde al menos un agonista nicotínico a7 y al menos un agente antisicótico son proveídos simultáneamente, secuencialmente, o separadamente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2828208P | 2008-02-13 | 2008-02-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6290706A2 true CO6290706A2 (es) | 2011-06-20 |
Family
ID=40902222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO10112124A CO6290706A2 (es) | 2008-02-13 | 2010-09-10 | Combinacion sinergica de un agonista nicotinico alfa 7 y un agente antipsicotico |
Country Status (26)
Country | Link |
---|---|
US (1) | US20110059947A1 (es) |
EP (2) | EP2254598B1 (es) |
JP (1) | JP2011511845A (es) |
KR (1) | KR20100113163A (es) |
CN (2) | CN101977628A (es) |
AU (1) | AU2009214625A1 (es) |
BR (1) | BRPI0907570A2 (es) |
CA (1) | CA2715268A1 (es) |
CO (1) | CO6290706A2 (es) |
CY (1) | CY1114492T1 (es) |
DK (1) | DK2254598T3 (es) |
EC (1) | ECSP10010471A (es) |
ES (1) | ES2430622T3 (es) |
HK (1) | HK1147954A1 (es) |
HR (1) | HRP20130749T1 (es) |
IL (1) | IL207389A0 (es) |
MX (1) | MX2010008875A (es) |
NZ (1) | NZ587312A (es) |
PL (1) | PL2254598T3 (es) |
PT (1) | PT2254598E (es) |
RS (1) | RS52941B (es) |
RU (1) | RU2481123C2 (es) |
SG (1) | SG188144A1 (es) |
SI (1) | SI2254598T1 (es) |
WO (1) | WO2009102962A2 (es) |
ZA (1) | ZA201005999B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8314119B2 (en) * | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
SA08290475B1 (ar) * | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
MX2013003344A (es) | 2010-09-23 | 2013-06-28 | Abbvie Inc | Monohidrato de un derivado de azaadamantano. |
KR20140011320A (ko) * | 2011-01-18 | 2014-01-28 | 타가셉트 인코포레이티드 | 정신분열증에서 인지 기능장애의 치료 |
US9139576B2 (en) | 2011-05-03 | 2015-09-22 | Merck Sharp & Dohme Corp. | Aminomethyl biaryl benzotriazole derivatives |
RU2015116816A (ru) * | 2012-10-02 | 2016-11-27 | Сумитомо Дайниппон Фарма Ко., Лтд. | Производное имидазола |
CA3047451A1 (en) | 2016-12-20 | 2018-06-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
KR102614709B1 (ko) | 2016-12-20 | 2023-12-18 | 에르테에스 로만 테라피-시스테메 아게 | 아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템 |
CN108727416B (zh) * | 2017-04-20 | 2021-03-09 | 北京大学 | 三环杂芳香体系酰胺衍生物及其制备和用途 |
BR112019027037B1 (pt) | 2017-06-26 | 2022-04-05 | Lts Lohmann Therapie-Systeme Ag | Sistema terapêutico transdérmico contendo asenapina e polímero híbrido acrílico de silicone, e processo para fabricar uma camada contendo asenapina para uso no referido sistema |
CN107469087A (zh) * | 2017-09-10 | 2017-12-15 | 孙永丽 | 用于治疗精神病的制剂 |
JP7502199B2 (ja) | 2018-06-20 | 2024-06-18 | エルテーエス ローマン テラピー-ジステーメ アーゲー | アセナピンを含有する経皮治療システム |
JP2024502470A (ja) * | 2021-01-08 | 2024-01-19 | アイエフエム デュー インコーポレイテッド | Sting活性に関連する状態を治療するための化合物および組成物 |
DE102022114269A1 (de) | 2022-06-07 | 2023-12-07 | Rational Aktiengesellschaft | Gargerät mit einem Selbstreinigungssystem sowie ein Verfahren zum Ändern von Reinigungsparametern für das Gargerät |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
US5712270A (en) * | 1995-11-06 | 1998-01-27 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
US5616716A (en) | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
US5663356A (en) * | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
AR013184A1 (es) | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
PT1083889E (pt) | 1998-06-01 | 2004-04-30 | Ortho Mcneil Pharm Inc | Compostos de tetra-hidronaftaleno e sua utilizacao no tratamento de doencas neurodegenerativas |
US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
SE9904176D0 (sv) | 1999-11-18 | 1999-11-18 | Astra Ab | New use |
WO2001041750A2 (en) * | 1999-12-10 | 2001-06-14 | Wyeth | Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics |
PL201530B1 (pl) * | 2000-06-27 | 2009-04-30 | L V A T Lab Sa | Karbaminiany pochodne aryloalkiloamin i zastosowanie karbaminianów pochodnych aryloalkiloamin |
US6492386B2 (en) | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
WO2002016357A2 (en) | 2000-08-18 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
EP1381603A2 (en) | 2000-08-18 | 2004-01-21 | PHARMACIA & UPJOHN COMPANY | Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands ) |
JP2004506734A (ja) | 2000-08-21 | 2004-03-04 | ファルマシア・アンド・アップジョン・カンパニー | 疾患治療用のキヌクリド置換ヘテロアリール部分 |
AU2001282875A1 (en) | 2000-08-21 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
US6599916B2 (en) | 2000-08-21 | 2003-07-29 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
US6554086B1 (en) * | 2000-10-27 | 2003-04-29 | Invacare Corporation | Obstacle traversing wheelchair |
KR100869722B1 (ko) | 2000-12-22 | 2008-11-21 | 알미랄 에이쥐 | 퀴누클리딘 카르바메이트 유도체 및 m3 길항제로서 그의사용 |
US6894042B2 (en) * | 2002-02-19 | 2005-05-17 | Pharmacia & Upjohn Company | Azabicyclic compounds for the treatment of disease |
AU2003302911A1 (en) * | 2002-12-06 | 2004-06-30 | Pharmacia & Upjohn Company | Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compostions and preparations thereof |
TW200502222A (en) * | 2003-04-02 | 2005-01-16 | Novartis Ag | Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders |
WO2004099202A1 (en) * | 2003-05-05 | 2004-11-18 | Pharmacia & Upjohn Company Llc | Quinuclidines substituted bentodioxine carboxamides for the treatment of neurodegenerative diseases |
US7309699B2 (en) * | 2003-12-22 | 2007-12-18 | Abbott Laboratories | 3-Quinuclidinyl amino-substituted biaryl derivatives |
JP2007516275A (ja) * | 2003-12-23 | 2007-06-21 | ファイザー・プロダクツ・インク | 認知増強および精神病性障害のための治療的組合せ |
CA2601509A1 (en) * | 2005-03-18 | 2006-09-28 | Abbott Laboratories | Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions |
-
2009
- 2009-02-13 CN CN2009801102033A patent/CN101977628A/zh active Pending
- 2009-02-13 NZ NZ587312A patent/NZ587312A/en not_active IP Right Cessation
- 2009-02-13 KR KR1020107020088A patent/KR20100113163A/ko not_active Application Discontinuation
- 2009-02-13 RS RS20130387A patent/RS52941B/en unknown
- 2009-02-13 DK DK09709577.2T patent/DK2254598T3/da active
- 2009-02-13 US US12/867,073 patent/US20110059947A1/en not_active Abandoned
- 2009-02-13 PL PL09709577T patent/PL2254598T3/pl unknown
- 2009-02-13 WO PCT/US2009/034062 patent/WO2009102962A2/en active Application Filing
- 2009-02-13 EP EP09709577.2A patent/EP2254598B1/en active Active
- 2009-02-13 EP EP13167089.5A patent/EP2633868A1/en not_active Withdrawn
- 2009-02-13 ES ES09709577T patent/ES2430622T3/es active Active
- 2009-02-13 MX MX2010008875A patent/MX2010008875A/es not_active Application Discontinuation
- 2009-02-13 SG SG2013010327A patent/SG188144A1/en unknown
- 2009-02-13 CN CN2013100500436A patent/CN103143023A/zh active Pending
- 2009-02-13 SI SI200930714T patent/SI2254598T1/sl unknown
- 2009-02-13 CA CA2715268A patent/CA2715268A1/en not_active Abandoned
- 2009-02-13 RU RU2010137787/15A patent/RU2481123C2/ru not_active IP Right Cessation
- 2009-02-13 BR BRPI0907570A patent/BRPI0907570A2/pt not_active IP Right Cessation
- 2009-02-13 PT PT97095772T patent/PT2254598E/pt unknown
- 2009-02-13 JP JP2010546920A patent/JP2011511845A/ja active Pending
- 2009-02-13 AU AU2009214625A patent/AU2009214625A1/en not_active Abandoned
-
2010
- 2010-08-03 IL IL207389A patent/IL207389A0/en unknown
- 2010-08-23 ZA ZA2010/05999A patent/ZA201005999B/en unknown
- 2010-09-09 EC EC2010010471A patent/ECSP10010471A/es unknown
- 2010-09-10 CO CO10112124A patent/CO6290706A2/es not_active Application Discontinuation
-
2011
- 2011-03-03 HK HK11102160.7A patent/HK1147954A1/xx not_active IP Right Cessation
-
2013
- 2013-08-07 HR HRP20130749AT patent/HRP20130749T1/hr unknown
- 2013-10-10 CY CY20131100896T patent/CY1114492T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP2633868A1 (en) | 2013-09-04 |
SG188144A1 (en) | 2013-03-28 |
CN103143023A (zh) | 2013-06-12 |
HRP20130749T1 (en) | 2013-10-11 |
KR20100113163A (ko) | 2010-10-20 |
EP2254598A2 (en) | 2010-12-01 |
US20110059947A1 (en) | 2011-03-10 |
CY1114492T1 (el) | 2016-10-05 |
PL2254598T3 (pl) | 2013-12-31 |
CN101977628A (zh) | 2011-02-16 |
BRPI0907570A2 (pt) | 2019-09-24 |
RS52941B (en) | 2014-02-28 |
SI2254598T1 (sl) | 2013-10-30 |
WO2009102962A3 (en) | 2009-10-08 |
DK2254598T3 (da) | 2013-07-29 |
IL207389A0 (en) | 2010-12-30 |
NZ587312A (en) | 2011-12-22 |
ECSP10010471A (es) | 2010-10-30 |
RU2010137787A (ru) | 2012-03-20 |
JP2011511845A (ja) | 2011-04-14 |
HK1147954A1 (en) | 2011-08-26 |
AU2009214625A1 (en) | 2009-08-20 |
ES2430622T3 (es) | 2013-11-21 |
ZA201005999B (en) | 2011-05-25 |
WO2009102962A2 (en) | 2009-08-20 |
RU2481123C2 (ru) | 2013-05-10 |
PT2254598E (pt) | 2013-10-16 |
CA2715268A1 (en) | 2009-08-20 |
EP2254598B1 (en) | 2013-07-10 |
MX2010008875A (es) | 2010-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6290706A2 (es) | Combinacion sinergica de un agonista nicotinico alfa 7 y un agente antipsicotico | |
CO2019005287A2 (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
CY1120961T1 (el) | Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος | |
AR062860A1 (es) | Combinaciones terapeuticas 482 | |
CL2018001420A1 (es) | Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853) | |
BRPI0517091B8 (pt) | composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida | |
CL2011000916A1 (es) | Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer. | |
CL2011001811A1 (es) | Un metodo para tratar un paciente que ha sufrido un infarto agudo al miocardio que comprende el uso de un agente antifibrotico. | |
CR20120345A (es) | Derivados de 3-hidroxi-5-arilisotiazol novedosos | |
CL2012002706A1 (es) | Composicion farmaceutica termogelificante estabilizada compuesta por anestesicos locales con un ph de al menos el pka de dichos anestesicos, que comprende a) la forma basica de uno o mas anestesicos de tipo amida, b) 10 a 30% de un aceite de ricino polioxietilado, y c) al menos 15% de uno o mas tensioactivos; y su metodo de preparacion. | |
CL2011000454A1 (es) | Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
EA200870376A1 (ru) | Бензотиазолы, обладающие активностью по отношению к h3-рецептору гистамина | |
CR20160544A (es) | Compuesto heterocíclico que contiene nitrógeno | |
ECSP056229A (es) | Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres | |
CL2008001038A1 (es) | Uso de una composicion que comprende un antagonosta h1, y un compuesto anti-tnf alfa para tratar conjuntivitis alegica o rinitis alergiva en un sujeto humano | |
BR112012021933A2 (pt) | método para processamento de soluções de peroxigênio. | |
PE20070618A1 (es) | Composicion farmaceutica que contiene rosiglitazona en el tratamiento de alzheimer | |
CL2008002369A1 (es) | Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer. | |
CL2013000313A1 (es) | Combinacion farmaceutica que comprende un farmaco antipsicotico atipico como olanzapina y un agonista de taar1; composicion farmaceutica que los comprende; y su uso para el tratamiento de la esquizofrenia y de los episodios de mania asociados al trastorno bipolar, con incidencia reducida de sindrome metabolico. | |
AR057643A1 (es) | Lacosamida para terapia adjunta | |
CL2008002049A1 (es) | Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
ECSP088555A (es) | Composiciones farmacéuticas | |
UY28225A1 (es) | Derivados azabiciclicos de piridiloximetilo y bencisoxazol | |
CL2009000665A1 (es) | Compuestos derivados de pirrolidinilo; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la ansiedad, depresion o ambas. | |
CL2008002700A1 (es) | Composicion farmaceutica que comprende 2-(2,4-difluoro-fenil)-6-[1-(2,6-difluoro-fenil)-ureido]-nicotinamida; envase farmaceutico; util en el tratamiento de artritis reumatoidea. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |